Dr Michael Flynn
Dr Flynn is a medical oncologist specialising in gynae-oncology and early phase trials. He has a translational PhD in antibody drug conjugate development and works academically at University College London.
Bio
Dr. Flynn is a highly skilled Medical Oncology Consultant with a robust background in translational research and clinical trials. He earned his PhD in antibody drug conjugate translational development from University College London, where he honed his expertise in targeted cancer therapies. Dr. Flynn completed his specialist oncology training at the prestigious Royal Marsden Hospital.
During his time as a Phase I Clinical Research Fellow at UCLH's Clinical Research Facility, Dr. Flynn gained extensive experience in early-phase clinical trials, serving as a sub-investigator on numerous first-in-man and later-stage development studies. He now leads as Principal Investigator on gynaecological-specific trials and plays a key role as a sub-investigator on tumour-agnostic targeted therapy, immunotherapy, and combination therapy trials. Dr. Flynn continues to expand his research portfolio, driving forward innovative cancer treatments to improve patient outcomes.
More information
Jun 2020- present:
- The London Clinic and LOC (London Oncology Care-HCA) practising privileges
- BUPA recognised provider
- University College London Hospital
- Consultant Medical Oncologist: Gynaecological Oncology, Acute Oncology and Early Phase Trials
- 2006, University of Witwatersrand, 2000-2006, MBBCh
- 2006 MBBCh (cum laude), University of Witwatersrand, Johannesburg
- 2011, MRCP 2016, University College London, 2013-2016, PhD
- 2006 MBBCh (cum laude), University of Witwatersrand, Johannesburg
- 2016 Doctor of Philosophy, University College London 2012 MRCP (UK)
- 2018, MRCP, Medical Oncology
- 2018 Specialty Certificate in Medical Oncology (UK)
-
2019 Postgraduate Diploma in Oncology, The University of London
- Associate Teaching Fellow UKHEA
- UCL iBSC oncology tutor
- 2022 American Association for Cancer Research
- 2018 European Society of Medical Oncology
- 2017 American Society of Clinical Oncology
- 2017 Association of Cancer Physicians
- Ovarian cancer recurrence: is the definition of platinum resistance modified by PARPi and other intervening treatments? The evolving landscape in the management of platinum-resistant ovarian cancer. Flynn MJ, Ledermann JA. Cancer Drug Resistance. 2022,5:424-35
- An in-depth review of niraparib in ovarian cancer: mechanism of action, clinical efficacy and future directions. Akay M, Funingana IG, Patel G, Mustapha R, Gjafa E, Ng T, Ng K, Flynn MJ Oncology and Therapy. 2021 Aug 7